Blood Transfusion - Process And Complications
Blood transfusion is the intravenous administration of blood or blood components to restore oxygen-carrying capacity, coagulation factors, or volume, with potential complications including hemolytic reactions, febrile non-hemolytic reactions, allergic reactions, transfusion-related acute lung injury (TRALI), and transfusion-associated circulatory overload (TACO).
Blood Transfusion — Process and Complications
Blood transfusion is the intravenous administration of blood components to correct deficiencies in oxygen-carrying capacity (red cells), haemostasis (platelets, clotting factors), or plasma volume. It is one of the most common interventions in hospital medicine, but carries real risks — from fatal ABO-incompatible haemolysis to subtle iron overload in chronically transfused patients.
What a safe clinician must not miss: ABO-incompatible transfusion is the single most dangerous iatrogenic error; the majority of fatal transfusion reactions are caused by clerical/identification errors, not laboratory failures. Every step from blood-bank request to bedside administration must include patient identity verification.
The first human-to-human transfusion was performed in London 1829 by Dr Blundell, an obstetrician, for postpartum haemorrhage. [1]
These are the 8 ideas you must internalise before memorising details [1][2]:
- Different kinds of blood products — know what each contains, how it is stored, and when to use it.
- Acute adverse reactions after transfusion — recognise and manage within minutes.
- Chronic complications from transfusion — infections, iron overload.
- How to prevent complications from transfusion — specialised products, screening, bedside checks.
- Restrictive vs liberal transfusion strategy — restrictive (transfuse at Hb < 7 g/dL) is now standard of care in most settings.
- Massive transfusion protocol — know the definition ( > 10 units or 1–2× blood volume), the empirical ratio, and the metabolic complications.
- Pre-transfusion testing — ABO/RhD grouping, antibody screening, crossmatch, infectious agent screening.
- Consent and documentation — transfusion is a procedure requiring informed consent.
Blood Products — Types, Processing, Storage, and Indications
Whole blood is NOT given in Hong Kong — blood is fractionated into components. [3]
| Product | Content / Processing | Storage | Indications | Dosing / Expected Effect |
|---|---|---|---|---|
| Red Cell Concentrate (Packed Cells) | Plasma removed, replaced with CPDA-1 anticoagulant + SAGM additive; Hct ~57% | Up to 35 days at 2–6°C | Hb < 7 g/dL (general); < 8 g/dL (IHD); clinical decision | 1 unit → ↑Hb by ~1.2 g/dL and ↑Hct by 3% in a 70 kg adult; paeds: 4 mL/kg → ↑Hb ~1 g/dL [3] |
| Platelet Concentrate | 1 adult dose from 4 whole-blood donations (pooled) or single apheresis; cultured for 24h before release (high bacterial risk at RT) | 5–7 days at 20–24°C on agitator | Thrombocytopenia thresholds (see table below); platelet dysfunction + bleeding | 1 adult dose → ↑PLT by 7–10 × 10⁹/L [3] |
| Fresh Frozen Plasma (FFP) | 150–300 mL; all soluble plasma proteins and clotting factors | Up to 2 years at −30°C | TTP (plasma exchange); massive transfusion; warfarin reversal with bleeding; PT/aPTT > 1.5× control + bleeding/procedure | 2–4 units adults; 12–15 mL/kg paeds [3] |
| Cryoprecipitate | Controlled thawing of FFP → precipitate rich in fibrinogen (150–300 mg), F8 (80–120 U), vWF; 20–50 mL/unit | Frozen | Fibrinogen < 1 g/L; vWD (if DDAVP/factor concentrate not suitable); F13 deficiency | 10 U/dose adults (raises fibrinogen ~1 g/L) [3] |
| White Cell Concentrate (Buffy Coat) | Pooled or apheresis; must be irradiated | RT for max 24h — must pre-arrange with HKRCBTS | Neutropenia ( < 0.5 × 10⁹/L) + documented infection unresponsive to broad-spectrum Abx + antifungals ≥48h | 10 U/day for ≥4 days [3] |
| Product | Indication |
|---|---|
| Human albumin | Volume expansion, hypoalbuminaemia |
| Clotting factor concentrate | Haemophilia A/B, specific factor deficiencies |
| Intravenous immunoglobulin (IVIg) | ITP, Kawasaki, immunodeficiency, GBS |
| Prothrombin complex concentrate (PCC) — 3-factor (II, IX, X) or 4-factor (II, VII, IX, X) | Similar to FFP but for torrential bleeding / ICH; provides ↑factors in ↓volume; risk: thrombosis [3] |
| Platelet Count | Setting |
|---|---|
| < 10 × 10⁹/L | Stable patients (except ITP, SLE, TTP, HUS) |
| < 20 × 10⁹/L | Fever / sepsis |
| < 50 × 10⁹/L | Major/mucosal bleeding; before invasive procedures; stable premature neonates |
| < 100 × 10⁹/L | CNS/retinal bleeding or surgery; post-cardiopulmonary bypass active bleeding; sick premature neonates |
This table is very high yield — it links product processing to the specific complication it prevents [3]:
| Product | Processing | Purpose | Indications |
|---|---|---|---|
| Leukodepleted blood | Pre-storage buffy-coat removal OR post-storage in-line leukocyte filter | Prevent FNHTR, HLA alloimmunisation, CMV transmission | Transfusion-dependent thalassaemia; haematological diseases; ≥2 severe FNHTR episodes; paed oncology [1][3][7] |
| Irradiated cellular components | 2500 cGy irradiation before transfusion | Inactivates donor lymphocytes → prevents TA-GVHD (otherwise 100% fatal) | Intrauterine transfusion; SCID; HSCT recipients; Hodgkin disease; purine analogue chemo; transfusion from 1° relatives [3] |
| CMV-seronegative components | Tested seronegative for CMV (not routine) | Prevent CMV transmission in immunocompromised | CMV-negative pregnant women; CMV-negative allo-HSCT recipients; intrauterine transfusion; HIV [3] |
| Rh(D)-negative red cells | Tested Rh(D) negative | Prevent Rh-haemolytic reaction / Rh(D) sensitisation in women of childbearing age | HDN due to anti-D; RhD-neg with anti-D; RhD-neg female before menopause; emergency resuscitation of Caucasian female with unknown RhD [3] |
Thalassaemia Transfusion
For thalassaemia major, use leukodepleted packed cells to ↓FNHTR and TRALI. Target: pre-transfusion Hb 9–10 g/dL, post-transfusion Hb ~14 g/dL. Frequency: every 4 weeks. Hyper-transfusion suppresses ineffective erythropoiesis and ↓GI iron absorption. [7]
The restrictive transfusion strategy (transfuse when Hb < 7 g/dL, aim 7–9 g/dL) is now standard in most clinical scenarios. [4][5]
| Clinical Setting | Transfusion Threshold | Target Hb | Rationale |
|---|---|---|---|
| General | Hb < 7 g/dL | 7–9 g/dL | Large RCT evidence: restrictive strategy ↓mortality at 6 weeks [4] |
| Acute variceal bleeding (cirrhosis) | Hb < 7 g/dL | 7–9 g/dL | Liberal transfusion engorges vasculature → ↑portal pressure → ↑rebleeding [4][5] |
| ACS / cardiovascular disease | Hb < 8 g/dL (consider 8–10 g/dL) | ≥8–9 g/dL | Avoid triggering adverse vascular events [4] |
| Haemodynamically unstable | Transfuse liberally | Guided by clinical response | Exceptions to restrictive strategy [4] |
| Critical care / HF / shock | Hb < 7–8 g/dL | 7–9 g/dL | Generally still restrict [3] |
| Thalassaemia major | Pre-transfusion Hb < 9–10 g/dL | Post-transfusion 14 g/dL | Suppress ineffective erythropoiesis [7] |
Exam Trap
Do NOT confuse the thresholds. The two exceptions to restrictive transfusion in UGIB are: (1) haemodynamically unstable patients and (2) underlying cardiovascular disease (especially ACS) — in these, transfuse more liberally. [4]
Key Steps Explained
- Consent: Explain risks (fever, allergy, infection, serious but rare reactions). Document.
- Pre-transfusion testing: ABO/RhD compatibility + infectious agent tests (HBV, HCV, HIV, syphilis) — done at HKRCBTS [3].
- Bedside check: The most critical safety step. Two staff independently verify patient identity against the blood unit label and compatibility form.
- Monitoring during transfusion: Baseline vitals → 15 min after start → then at least hourly. Most severe reactions occur within the first 15 minutes.
- Unit-by-unit transfusion is now preferred: Reassess Hb after each unit — often 1 unit is sufficient. Traditional 2-unit ordering is outdated. [3]
Complications of Blood Transfusion
| Timing | Immune-Mediated | Non-Immune-Mediated |
|---|---|---|
| Acute (< 24h) | AHTR, FNHTR, allergic/anaphylaxis, TRALI | Bacterial contamination, TACO, air embolism, primary hypotensive reaction |
| Delayed | DHTR, TA-GVHD, post-transfusion purpura, HLA alloimmunisation | Infections (viral, parasitic, prion), iron overload (haemosiderosis) |
| Massive transfusion specific | — | Hypothermia, coagulopathy, hyperkalaemia, citrate toxicity (↓Ca²⁺), metabolic alkalosis |
Acute Complications (< 24 hours)
The most common symptoms reported in acute transfusion reactions are: fever, chills, pruritus, urticaria. [1]
- Incidence: ~3% (commonest reaction) [6]
- Pathogenesis: HLA Class I antigens are carried in high concentrations by leucocytes and platelets → reaction with patient's HLA antibodies → cytokine release from stored WBCs [8][9]
- S/S: Temperature rise ≥1°C, chills/rigors during or shortly after transfusion; patient otherwise well
- Management:
- Prevention: Leukodepleted blood products [3][8]
Key Distinction
Fever during transfusion ≠ automatic stop. You MUST exclude the dangerous causes (ABO incompatibility, bacterial contamination) first, but if it's FNHTR → treat symptomatically and continue. If it was ABO incompatibility or bacterial contamination → stop immediately. [1]
- Incidence: ~1/6,000 [6]
- Pathogenesis: ABO-incompatible red cells → pre-formed IgM anti-A or anti-B activate complement → intravascular haemolysis → DIC → renal failure
- S/S: Within minutes of starting transfusion — fever, rigors, back/loin pain, chest tightness, hypotension, dark urine (haemoglobinuria), DIC
- Management:
- STOP transfusion immediately — do NOT restart
- Keep IV line open with NS
- Resuscitate: fluids, vasopressors if needed
- Send: blood unit + IV set to lab; repeat group/crossmatch; direct antiglobulin test (DAT); serum for free Hb, haptoglobin, bilirubin, LDH; urine for haemoglobin
- Monitor urine output (Foley's catheter) — maintain > 100 mL/h to prevent acute renal failure
- Manage DIC if it develops (FFP, cryoprecipitate, platelets)
- Report to blood bank and HKRCBTS
- Root cause: Almost always a clerical error — wrong patient, wrong label, wrong unit
- Urticaria: ~1% incidence [6]; localised hives/itch; due to reaction to donor plasma proteins
- Mx: Antihistamines; can often continue transfusion after symptoms settle
- Anaphylaxis: ~1/150,000 [6]; generalised urticaria, bronchospasm, hypotension, laryngeal oedema
- Classically in IgA-deficient patients with anti-IgA antibodies reacting to donor IgA
- Mx: STOP transfusion; IM adrenaline; ABC approach; IV fluids; future: use washed blood products or IgA-deficient donor products
- Incidence: < 1/10,000 [6]
- Pathogenesis: Donor's HLA Class I and/or II antibodies form immune complexes with corresponding HLA antigens of the patient → deposition on lung tissue → non-cardiogenic pulmonary oedema [8][9]
- S/S: Acute respiratory distress, bilateral pulmonary infiltrates, hypoxia within 6h of transfusion; NO evidence of circulatory overload (normal CVP)
- Dx: Clinical; CXR bilateral infiltrates; normal CVP (differentiates from TACO)
- Mx: Supportive — O₂, ventilation if needed; usually resolves within 48–72h
- Prevention: Leukodepleted products; avoid plasma from multiparous female donors (who have higher rates of HLA antibodies)
TRALI vs TACO differentiation is a classic exam question:
- TRALI: normal/low CVP, non-cardiogenic pulmonary oedema, onset < 6h
- TACO: ↑CVP with pulmonary oedema, onset 6–12h, responds to diuretics [3]
- Incidence: 0.2/10⁶ units for RBCs, 10/10⁶ units for platelets (50× higher risk for platelets) [3]
- Pathogenesis:
- S/S: Rapid onset of chills/rigors, high fever (usually > 2°C rise), N/V/D, hypotension — can mimic AHTR with DIC, intravascular haemolysis, renal failure [3]
- Management:
- STOP transfusion, change set, keep IV open with NS
- Urgent Gram stain of implicated unit
- Blood cultures from patient AND unit
- Broad-spectrum antibiotics with adequate anti-pseudomonal coverage
- Monitor for septic shock (vitals, I/O)
- Report to HKRCBTS [3]
- Incidence: 1/10,000 [3]
- Pathogenesis: Volume overload from any blood component; risk factors: pre-existing HF, CKD, elderly
- S/S: Respiratory distress (SOB, orthopnoea) in 6–12h of completing transfusion
- Dx: ↑CVP with pulmonary oedema (differentiates from TRALI) [3]
- Mx: O₂, diuretics ± ventilation; slow transfusion rate in future
Delayed Complications
- Onset: 3–14 days post-transfusion
- Pathogenesis: Anamnestic antibody response to minor red cell antigens (e.g. Kidd, Duffy, Kell); prior sensitisation from transfusion or pregnancy
- S/S: Falling Hb despite transfusion, mild jaundice, positive DAT
- Mx: Usually self-limiting; identify antibody for future transfusions
- Pathogenesis: Immunocompetent donor lymphocytes engraft in immunocompromised recipient → mount immune attack on host BM, skin, liver, GI
- S/S: Profound BM suppression, rash, liver dysfunction, diarrhoea → virtually 100% fatal [3]
- Prevention: Irradiated cellular components (2500 cGy) — indications listed above [3]
- Rare; thrombocytopenia 5–10 days post-transfusion due to anti-platelet antibodies (usually anti-HPA-1a)
- Mx: IVIg; future: HPA-1a-negative platelets
Risk of infections is not negligible as screening is not always accurate. [3]
| Agent | Estimated Risk | Notes |
|---|---|---|
| HBV | 1:3,000–1:10,000 | Most common transfusion-transmitted viral infection in HK [3][6] |
| HCV | 1:300,000 | [3] |
| HIV 1/2 | < 1:1,000,000 | [3] |
| CMV | Common; 40% adults seropositive | Serious in immunocompromised; prevented by leukodepletion or CMV-seronegative products [3] |
| HTLV-1 | Rare | Causes adult T-cell leukaemia/lymphoma or tropical spastic paraparesis [3] |
| Human parvovirus B19 | 1:10,000 | Aplastic crisis in chronic haemolysis [3] |
| Bacterial | See above | Yersinia, Pseudomonas (cold-resistant); skin flora [3] |
| Malaria (Plasmodium spp) | Rare in HK | Screened by travel history [3][6] |
| Trypanosoma cruzi | Rare | Chagas disease [3] |
| Prion (vCJD) | Cannot be screened | PrP mainly on B-lymphoid cells; infectivity: WBC > plasma > albumin [3] |
| Treponema pallidum | Rare | Serology not accurate enough [3] |
Measures to decrease risk of transfusion-related infections [3]:
- Donor screening questionnaire (travel, risk behaviours)
- Serological and NAT (nucleic acid testing) for HBV, HCV, HIV, syphilis
- Bacterial culture of platelet units (24h)
- Leukodepletion (↓CMV, HTLV-1)
- Pathogen inactivation (methylene blue for paediatric FFP in HK)
Massive transfusion = transfusion of > 10 units (or 1–2× patient's blood volume) [2][6]
Indications: severe trauma, ruptured AAA, obstetric haemorrhage [6]
Empirical ratio: packed cells : FFP : platelets = 1:1:1 (with repeated blood sampling for Hb, clotting profile) [6]
| Complication | Mechanism | Key Detail |
|---|---|---|
| Hypothermia | Each unit at 4°C → requires 1255 kJ to warm to 37°C | Use blood warmer for massive transfusion [2] |
| Coagulopathy | Haemodilution of clotting factors; Factor V and VIII decline quickly within 24h after collection | Replace with FFP, cryoprecipitate [2] |
| Hyperkalaemia | K⁺ leaks from stored RBCs (40–70 mmol/L in stored blood); older units worse | Monitor K⁺; use ECG monitoring [2][6] |
| Citrate toxicity → Hypocalcaemia | Citrate anticoagulant chelates Ca²⁺ → ↓ionised Ca²⁺ → cardiac dysfunction | Give IV calcium gluconate [2][6] |
| Metabolic alkalosis | Citrate and lactate in stored blood are metabolised to HCO₃⁻ | Paradoxical: initial acidosis from citrate/lactate, then delayed alkalosis [6] |
| 2,3-DPG degradation | Stored blood has ↓2,3-DPG → left-shifted O₂ dissociation curve → ↓O₂ delivery to tissues | [2] |
| Immunomodulation | ↑ratio of suppressor to helper T-cells → ↑infection risk | Relevant in cancer surgery — transfusion-related immunosuppression → ↑recurrence risk [2][6] |
Massive Transfusion Mnemonic: 'CHICK-M'
Coagulopathy, Hypothermia, hyperK (Ion), Citrate toxicity (hypoCa²⁺), K (metabolic alKalosis), M (immunoModulation / 2,3-DPG)
Iron Overload (Haemosiderosis)
- Each 500 mL blood contains ~250 mg iron = 8 months' worth of dietary iron [10]
- Body has no good mechanism for iron excretion → chronic transfusion → iron overload → toxic to the heart (cardiomyopathy), liver (cirrhosis), endocrine (diabetes, hypogonadism) [10]
- Management: Iron chelation — Desferrioxamine (DFO), Deferiprone (DFP), Deferasirox → bind iron, excrete via urine and faeces [10]
- Critical in thalassaemia major patients on regular transfusion
Special Situations and Modifications
- Transfusion causes immunosuppression → ↑risk of recurrence → higher threshold / avoid transfusion if possible after curative cancer surgery [6]
- Blood transfusion causes falsely low HbA1c (new donor RBCs not yet glycosylated) — important to remember when monitoring diabetic patients who have been recently transfused [11]
Exam Approach
- Expect scenarios: "Patient develops fever 30 min into transfusion — what is the most likely diagnosis and management?"
- Know the differentiation table: FNHTR vs AHTR vs bacterial contamination vs TRALI vs TACO
- Know platelet transfusion thresholds by clinical setting
- Know massive transfusion complications and the 1:1:1 ratio
- Know specialised products and which complication each prevents
- Bedside management of acute transfusion reaction (stepwise protocol)
- Counselling patient about need for transfusion — explain risks in lay terms
- Prescribing blood products: "I would prescribe 1 unit of leukodepleted packed red cells to be transfused over 2–4 hours with vital sign monitoring at baseline, 15 minutes, and then hourly"
- Assuming all fever = stop transfusion (FNHTR → can continue)
- Forgetting to check patient identity at bedside
- Confusing TRALI (normal CVP) with TACO (raised CVP)
- Not knowing that platelets have 50× higher bacterial contamination risk than RBCs
- Forgetting citrate toxicity → hypocalcaemia in massive transfusion
High Yield Summary
- Blood components in HK: packed cells, platelets, FFP, cryoprecipitate, buffy coat; whole blood is NOT used [3]
- Restrictive transfusion (Hb < 7 g/dL) is standard; exceptions: ACS (< 8), haemodynamically unstable (liberal) [4][6]
- Most common acute reaction: FNHTR — give paracetamol, continue transfusion after excluding serious causes [1]
- Most dangerous: AHTR from ABO incompatibility — almost always a clerical error [3]
- TRALI: donor HLA antibodies + recipient HLA antigens → lung immune complex deposition → normal CVP [8][9]
- TACO: volume overload → ↑CVP → diuretics [3]
- Bacterial contamination: platelets >> RBCs; cold-resistant organisms: Yersinia, Pseudomonas [3]
- Massive transfusion ( > 10 units): 1:1:1 ratio; complications = hypothermia, coagulopathy, hyperK⁺, citrate toxicity (↓Ca²⁺), metabolic alkalosis [2][6]
- Specialised products: leukodepleted (↓FNHTR/TRALI), irradiated (↓TA-GVHD — 100% fatal if missed), CMV-negative, RhD-negative [3]
- Iron overload in chronic transfusion: 250 mg Fe per unit; chelation with DFO/DFP/Deferasirox [10]
Active Recall - Blood Transfusion
[1] Senior notes: Block A - Fever after a blood transfusion_ transfusion and related problems.pdf [2] GC lecture slides: GC 188. Hit by a van, in shock with internal bleeding Abdominal injury.pdf (p26) [3] Senior notes: Ryan Ho Haemtology.pdf (pp142–151) [4] Senior notes: Block A - Coffee ground vomitus tarry stool upper GI bleeding.pdf (pp13–14) [5] Senior notes: Block A - Abdominal distension_ ascites and cirrhosis.pdf (p8) [6] GC lecture slides / CFB lecture slides: CFB 22_WCS FLUID ELECTROLYTES TRANSFUSION_r20240814.pdf (pp25, 32); Ryan Ho Critical Care.pdf (p20) [7] Senior notes: Adrian Lui Pediatrics Notes.pdf (p366) [8] Lecture slides: Laboratory Diagnostic Investigations Seminar_Tissue typing and transplant immunology_2025 - Dr J Kwok.pdf (pp131–132) [9] GC lecture slides: GC 049. Fever after a blood transfusion.pdf (pp1–2) [10] Senior notes: Block A - Hematology Interactive Tutorial.pdf (p5) [11] Senior notes: Block A - Polyuria and polydipsia_ glucose metabolism; diabetes mellitus; diabetic ketoacidosis.pdf (p4)
Waldenström Macroglobulinaemia
Waldenström macroglobulinaemia is a lymphoplasmacytic lymphoma characterized by clonal proliferation of B lymphocytes in the bone marrow with overproduction of monoclonal immunoglobulin M (IgM), leading to hyperviscosity and cytopenias.
Meningitis
Meningitis is an inflammation of the meninges surrounding the brain and spinal cord, most commonly caused by infectious agents such as bacteria, viruses, or fungi, presenting with headache, neck stiffness, and fever.